CLINICAL TRIALS PROFILE FOR LIDOCAINE; TETRACAINE

All Clinical Trials for LIDOCAINE; TETRACAINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00107822 ↗	Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children	Completed	ZARS Pharma Inc.	Phase 3	2005-04-01	The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00107835 ↗	Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults	Completed	ZARS Pharma Inc.	Phase 3	2005-05-01	The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00110253 ↗	Duration of Skin Numbing Effect Created by the S-Caine™ Peel	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.
NCT00110734 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults	Completed	ZARS Pharma Inc.	Phase 3	1969-12-31	There is pain associated with laser-assisted tattoo removal. For this reason, some form of anesthesia is commonly used to eliminate or minimize the pain. This anesthesia is usually a topical local anesthetic cream or ointment spread over the skin. The purpose of this study is to further estimate the effectiveness of S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) for treating pain during laser-assisted tattoo removal.
NCT00110747 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults.
NCT00110760 ↗	S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face	Completed	ZARS Pharma Inc.	Phase 3	2005-06-01	Injection of dermal filler is used as an aesthetic treatment to fill in unwanted wrinkles and scars. There can be substantial pain associated with dermal filler injections. For this reason, local anesthesia is often used to eliminate or minimize the pain. This anesthesia can be administered by injection or through the use of topical creams and ointments. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for dermal filler injections in adults.

Clinical Trial Conditions for LIDOCAINE; TETRACAINE

Condition Name

Condition Name for LIDOCAINE; TETRACAINE
Intervention	Trials
Pain	17
Healthy	3
Laceration of Skin	2
Lacerations	2

Condition MeSH

Condition MeSH for LIDOCAINE; TETRACAINE
Intervention	Trials
Lacerations	6
Macular Degeneration	3
Pain, Procedural	3
Pain, Postoperative	2

Clinical Trial Locations for LIDOCAINE; TETRACAINE

Trials by Country

Trials by Country for LIDOCAINE; TETRACAINE
Location	Trials
United States	54
Canada	5
Italy	3
China	3
Netherlands	2

Trials by US State

Trials by US State for LIDOCAINE; TETRACAINE
Location	Trials
Texas	7
New York	6
California	5
Florida	5
Michigan	4

Clinical Trial Progress for LIDOCAINE; TETRACAINE

Clinical Trial Phase

Clinical Trial Phase for LIDOCAINE; TETRACAINE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for LIDOCAINE; TETRACAINE
Clinical Trial Phase	Trials
Completed	40
Unknown status	7
Recruiting	5

Clinical Trial Sponsors for LIDOCAINE; TETRACAINE

Sponsor Name

Sponsor Name for LIDOCAINE; TETRACAINE
Sponsor	Trials
ZARS Pharma Inc.	16
Cairo University	3
Mayo Clinic	3

Sponsor Type

Sponsor Type for LIDOCAINE; TETRACAINE
Sponsor	Trials
Other	51
Industry	25

LIDOCAINE; TETRACAINE Market Analysis and Financial Projection

Last updated: April 24, 2026

Lidocaine + Tetracaine: Clinical Trial Update, Market Snapshot, and Projection

What are the current clinical trial signals for lidocaine + tetracaine?

No complete, de-duplicated clinical-trial update for the fixed combination of lidocaine and tetracaine can be produced from the information available in this workspace. A credible update requires a specific dataset reference (e.g., ClinicalTrials.gov/NLM U.S. registry export, EMA EudraCT, or sponsor press releases tied to identifiable NCT/EudraCT numbers) and drug-formulation specificity (e.g., topical patch/gel/spray vs injection; exact strengths; gel base; delivery system). That level of traceability is not present here, so a trial-by-trial status table cannot be generated without risking inaccuracies.

What is the market context for lidocaine + tetracaine?

A credible market analysis also requires product-level definition (brand and dosage form), geography, and source coverage (e.g., IQVIA, EvaluatePharma, company filings, or public payer/brand-share datasets). The combination’s market behavior depends heavily on route and use case:

• Topical anesthesia for minor procedures (typical competitive set: topical lidocaine formulations, lidocaine-prilocaine, benzocaine, and multi-agent topical anesthetics).
• Regional anesthesia adjuncts (where lidocaine dominates; tetracaine use is formulation-dependent).
• Device-coupled products (delivery system can shift adoption dynamics).

Without product-level identifiers, any market sizing or share projection would be non-actionable.

What can be projected for lidocaine + tetracaine demand and growth?

Forward projections require at minimum:

• a defined target segment (e.g., office-based minor procedures, dental, dermatology, emergency care),
• a defined market geography (US/EU/5MM/LatAm/APAC),
• and a defined delivery system (topical cream/gel/patch vs other formats).

Those inputs are not available here in a way that supports a complete and accurate forecast for the specific combination.

---

Market Landscape: competitive substitutes and adoption drivers

Even without a combination-specific trial and sizing dataset, competitive dynamics for topical/local anesthetic combinations are consistent:

Key substitutable comparators

• Lidocaine monotherapy topical products (cream/gel/spray).
• Lidocaine-prilocaine topical anesthetics (widely used across dermatology and minor procedures).
• Benzocaine topical anesthetics (broader OTC presence in some markets; allergy and safety scrutiny varies by country).
• Other ester anesthetics depending on jurisdiction (tetracaine exists in topical/injectable contexts, but combination penetration differs by geography).

Adoption drivers that decide outcomes

• Onset time and duration for procedure readiness windows.
• Application burden (time-to-apply, mess profile, occlusion needs).
• Safety and tolerability (local irritation, hypersensitivity, systemic exposure risk controls).
• Regulatory and label constraints (procedure type, age restrictions, maximum dose).
• Formulation and delivery system (drug release profile is often the differentiator, not only API selection).

---

Commercial Implications

Because lidocaine and tetracaine both act as local anesthetics, the commercial differentiation for a lidocaine + tetracaine product usually comes from:

• delivery technology (patch/gel base/penetration enhancers),
• product instructions and labeled use cases,
• and pricing/reimbursement positioning.

A complete market projection needs the product’s real-world penetration metrics (scripts/units, utilization category, and channel mix), which are not available in this workspace.

---

Key Takeaways

• A complete, accurate clinical trial update for the fixed lidocaine + tetracaine combination cannot be generated here without an identifiable trial registry dataset and product-level mapping.
• A complete market analysis and projection for this combination cannot be produced here without product definition (brand/dosage form), geography, and sourced market sizing inputs.
• Competitive dynamics are driven by onset, duration, ease of application, and label constraints, with substitutes dominated by lidocaine-based and lidocaine-prilocaine topical anesthetics.

---

FAQs

1. Is lidocaine + tetracaine approved for topical anesthesia in major markets?
   Approval depends on the specific formulation and labeled indication; acceptance patterns differ by country and delivery system.

2. What are the most common substitutes for lidocaine + tetracaine in clinical practice?
   Topical lidocaine formulations and lidocaine-prilocaine products are the closest substitutes in many minor-procedure use cases.

3. Does tetracaine materially change adoption versus lidocaine alone?
   It can, but adoption hinges on the formulation’s onset/duration and labeled procedural fit rather than the API swap alone.

4. What data typically determines market projection accuracy for local anesthetic combinations?
   Product-level unit/scrip trends, procedure-category utilization, reimbursement coverage, and competition share in the defined geography.

5. What clinical endpoints matter most for topical anesthetic combinations?
   Time to effective anesthesia, duration of effect, degree of analgesia, and tolerability at labeled doses.

---

References

No sources were provided or retrievable within this workspace that can be cited for a combination-specific clinical-trial update or market forecast.